Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13430622 | 0.83 | KMT2A (0.43) | KDM4EALDH1A1RAB9ATDP1HPGD | |
| SCHEMBL4556787 | 0.81 | TDP1 (0.54) | CNR2KDM4EALDH1A1POLBRAB9A | |
| SCHEMBL5010673 | 0.81 | DHODH (0.60) | KDM4EALDH1A1RAB9ATDP1L3MBTL1 | |
| SCHEMBL20546008 | 0.81 | KDM4E (0.58) | CNR2KDM4EALDH1A1POLBRAB9A | |
| SCHEMBL12426304 | 0.79 | CNR2 (0.60) | CNR2KDM4EALDH1A1POLBRAB9A | |
| SCHEMBL10828788 | 0.79 | RAB9A (0.40) | KDM4EALDH1A1POLBRAB9ATDP1 | |
| SCHEMBL10828785 | 0.79 | RAB9A (0.40) | KDM4EALDH1A1POLBRAB9ATDP1 | |
| SCHEMBL11492008 | 0.77 | KDM4E (0.54) | CNR2KDM4EALDH1A1POLBRAB9A | |
| SCHEMBL28636454 | 0.77 | TDP1 (0.47) | CNR2KDM4EALDH1A1POLBRAB9A | |
| SCHEMBL21958052 | 0.77 | TDP1 (0.47) | CNR2KDM4EALDH1A1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115872926-A | Preparation method of triazole antifungal drug and intermediate thereof | 南通诺泰生物医药技术有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115772121-A | Preparation method of 2-methylamino-3-hydroxymethylpyridine | 南通诺泰生物医药技术有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-104961675-A | Preparation method of isavuconazole intermediate | CHENGDU SYNS PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-10-07 | — | — | CN | disclosed |
| US-7459561-B2 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2008-12-02 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | CNR2 1790/4885KDM4E 291/4885ALDH1A1 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.